Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study

{ 'indexed': {'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T10:18:03Z', 'timestamp': 1688206683656}, 'reference-count': 38, 'publisher': 'Springer Science and Business Media LLC', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2021, 9, 16]], 'date-time': '2021-09-16T00:00:00Z', 'timestamp': 1631750400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2021, 9, 16]], 'date-time': '2021-09-16T00:00:00Z', 'timestamp': 1631750400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 12]]}, 'DOI': '10.1007/s40744-021-00373-1', 'type': 'journal-article', 'created': {'date-parts': [[2021, 9, 16]], 'date-time': '2021-09-16T12:13:30Z', 'timestamp': 1631794410000}, 'page': '1887-1895', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients ' 'with Immune-Mediated Inflammatory Diseases: A Cohort Study', 'prefix': '10.1007', 'volume': '8', 'author': [ {'given': 'Debellemanière', 'family': 'Guillaume', 'sequence': 'first', 'affiliation': []}, {'given': 'Bouvet', 'family': 'Magalie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elahi', 'family': 'Sina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Salah-Mabed', 'family': 'Imène', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vayr', 'family': 'Frédéric', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dubois', 'family': 'Mathieu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Muselier', 'family': 'Aurore', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gozlan', 'family': 'Yoni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elbaz', 'family': 'Emma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Badatcheff', 'family': 'Charlotte', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabre', 'family': 'Laura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saad', 'family': 'Alain', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nahaisi', 'family': 'Steven', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zeboulon', 'family': 'Pierre', 'sequence': 'additional', 'affiliation': []}, {'given': 'Febbraro', 'family': 'Jean-Luc', 'sequence': 'additional', 'affiliation': []}, {'given': 'Courtin', 'family': 'Romain', 'sequence': 'additional', 'affiliation': []}, {'given': 'Grise-Dulac', 'family': 'Alice', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mazharian', 'family': 'Adrien', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ghazal', 'family': 'Wassim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Remongin', 'family': 'Pierre-Emmanuel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Panthier', 'family': 'Christophe', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chirouze', 'family': 'Catherine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bertrand', 'family': 'Kevin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sené', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gatinel', 'family': 'Damien', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 9, 16]]}, 'reference': [ { 'issue': '1', 'key': '373_CR1', 'doi-asserted-by': 'publisher', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'volume': '6', 'author': 'J Liu', 'year': '2020', 'unstructured': 'Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a ' 'less toxic derivative of chloroquine, is effective in inhibiting ' 'SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.', 'journal-title': 'Cell Discov'}, { 'issue': '15', 'key': '373_CR2', 'doi-asserted-by': 'publisher', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'volume': '71', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral ' 'activity and projection of optimized dosing design of hydroxychloroquine ' 'for the treatment of severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–9.', 'journal-title': 'Clin Infect Dis'}, { 'issue': '1', 'key': '373_CR3', 'doi-asserted-by': 'publisher', 'first-page': '105949', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'volume': '56', 'author': 'P Gautret', 'year': '2020', 'unstructured': 'Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. ' 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial. Int J Antimicrob Agents. ' '2020;56(1):105949.', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '373_CR4', 'doi-asserted-by': 'publisher', 'first-page': '101791', 'DOI': '10.1016/j.tmaid.2020.101791', 'volume': '36', 'author': 'J-C Lagier', 'year': '2020', 'unstructured': 'Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, ' 'Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated ' 'with hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.', 'journal-title': 'Travel Med Infect Dis'}, { 'issue': '2', 'key': '373_CR5', 'doi-asserted-by': 'publisher', 'first-page': '755', 'DOI': '10.1002/jmv.26286', 'volume': '93', 'author': 'A Ferreira', 'year': '2021', 'unstructured': 'Ferreira A, Oliveira-E-Silva A, Bettencourt P. Chronic treatment with ' 'hydroxychloroquine and SARS-CoV-2 infection. J Med Virol. ' '2021;93(2):755–9.', 'journal-title': 'J Med Virol'}, { 'key': '373_CR6', 'doi-asserted-by': 'publisher', 'first-page': '314', 'DOI': '10.1016/j.ijid.2021.04.035', 'volume': '106', 'author': 'RCS Seet', 'year': '2021', 'unstructured': 'Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et ' 'al. Positive impact of oral hydroxychloroquine and povidone-iodine ' 'throat spray for COVID-19 prophylaxis: an open-label randomized trial. ' 'Int J Infect Dis. 2021;106:314–22.', 'journal-title': 'Int J Infect Dis'}, { 'issue': '24', 'key': '373_CR7', 'doi-asserted-by': 'publisher', 'first-page': '2493', 'DOI': '10.1001/jama.2020.8630', 'volume': '323', 'author': 'ES Rosenberg', 'year': '2020', 'unstructured': 'Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, ' 'et al. Association of treatment with hydroxychloroquine or azithromycin ' 'with in-hospital mortality in patients with COVID-19 in New York State. ' 'JAMA. 2020;323(24):2493–502.', 'journal-title': 'JAMA'}, { 'issue': '6', 'key': '373_CR8', 'doi-asserted-by': 'publisher', 'first-page': '837', 'DOI': '10.1136/annrheumdis-2020-217566', 'volume': '79', 'author': 'A Mathian', 'year': '2020', 'unstructured': 'Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, ' 'Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 ' '(COVID-19) in a series of 17 patients with systemic lupus erythematosus ' 'under long-term treatment with hydroxychloroquine. Ann Rheum Dis. ' '2020;79(6):837–9.', 'journal-title': 'Ann Rheum Dis'}, { 'issue': '10', 'key': '373_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1386', 'DOI': '10.1136/annrheumdis-2020-217690', 'volume': '79', 'author': 'MF Konig', 'year': '2020', 'unstructured': 'Konig MF, Kim AHJ, Scheetz MH, Graef ER, Liew JW, Simard J, et al. ' 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does ' 'not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. ' '2020;79(10):1386–8.', 'journal-title': 'Ann Rheum Dis'}, { 'key': '373_CR10', 'doi-asserted-by': 'publisher', 'author': 'E Sbidian', 'year': '2020', 'unstructured': 'Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, et ' 'al. Comment on “Baseline use of hydroxychloroquine in systemic lupus ' 'erythematosus does not preclude SARS-CoV-2 infection and severe ' 'COVID-19” by Konig et al. Long-term exposure to hydroxychloroquine or ' 'chloroquine and the risk of hospitalisation with COVID-19: a nationwide, ' 'observational cohort study in 54,873 exposed individuals and 155,689 ' 'matched unexposed individuals in France. Ann Rheum Dis. 2020. ' 'https://doi.org/10.1136/annrheumdis-2020-218647.', 'journal-title': 'Ann Rheum Dis', 'DOI': '10.1136/annrheumdis-2020-218647'}, { 'issue': '7', 'key': '373_CR11', 'doi-asserted-by': 'publisher', 'first-page': '859', 'DOI': '10.1136/annrheumdis-2020-217871', 'volume': '79', 'author': 'M Gianfrancesco', 'year': '2020', 'unstructured': 'Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, ' 'et al. Characteristics associated with hospitalisation for COVID-19 in ' 'people with rheumatic disease: data from the COVID-19 Global ' 'Rheumatology Alliance physician-reported registry. Ann Rheum Dis. ' '2020;79(7):859–66.', 'journal-title': 'Ann Rheum Dis'}, { 'issue': '1', 'key': '373_CR12', 'doi-asserted-by': 'publisher', 'first-page': 'e19', 'DOI': '10.1016/S2665-9913(20)30378-7', 'volume': '3', 'author': 'CT Rentsch', 'year': '2021', 'unstructured': 'Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et ' 'al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 ' 'mortality: a population-based cohort study in patients with rheumatoid ' 'arthritis or systemic lupus erythematosus using the OpenSAFELY platform. ' 'Lancet Rheumatol. 2021;3(1):e19-27.', 'journal-title': 'Lancet Rheumatol'}, { 'issue': '25', 'key': '373_CR13', 'doi-asserted-by': 'publisher', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'volume': '382', 'author': 'J Geleris', 'year': '2020', 'unstructured': 'Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. ' 'Observational study of hydroxychloroquine in hospitalized patients with ' 'Covid-19. N Engl J Med. 2020;382(25):2411–8.', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '373_CR14', 'doi-asserted-by': 'publisher', 'first-page': 'e0251262', 'DOI': '10.1371/journal.pone.0251262', 'volume': '16', 'author': 'D Sammartino', 'year': '2021', 'unstructured': 'Sammartino D, Jafri F, Cook B, La L, Kim H, Cardasis J, et al. ' 'Predictors for inpatient mortality during the first wave of the ' 'SARS-CoV-2 pandemic: a retrospective analysis. PLoS ONE. ' '2021;16(5):e0251262.', 'journal-title': 'PLoS ONE'}, { 'key': '373_CR15', 'doi-asserted-by': 'publisher', 'author': 'H Gerlovin', 'year': '2021', 'unstructured': 'Gerlovin H, Posner DC, Ho Y-L, Rentsch CT, Tate JP, King JT Jr, et al. ' 'Pharmacoepidemiology, machine learning and COVID-19: an intent-to-treat ' 'analysis of hydroxychloroquine, with or without azithromycin, and ' 'COVID-19 outcomes amongst hospitalized US Veterans. Am J Epidemiol. ' '2021. https://doi.org/10.1093/aje/kwab183.', 'journal-title': 'Am J Epidemiol', 'DOI': '10.1093/aje/kwab183'}, { 'issue': '21', 'key': '373_CR16', 'doi-asserted-by': 'publisher', 'first-page': '2041', 'DOI': '10.1056/NEJMoa2019014', 'volume': '383', 'author': 'AB Cavalcanti', 'year': '2020', 'unstructured': 'Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et ' 'al. Hydroxychloroquine with or without azithromycin in mild-to-moderate ' 'Covid-19. N Engl J Med. 2020;383(21):2041–52.', 'journal-title': 'N Engl J Med'}, { 'issue': '2', 'key': '373_CR17', 'doi-asserted-by': 'publisher', 'first-page': 'E693', 'DOI': '10.9778/cmajo.20210069', 'volume': '9', 'author': 'I Schwartz', 'year': '2021', 'unstructured': 'Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, et ' 'al. Assessing the efficacy and safety of hydroxychloroquine as ' 'outpatient treatment of COVID-19: a randomized controlled trial. CMAJ ' 'Open. 2021;9(2):E693-702.', 'journal-title': 'CMAJ Open'}, { 'key': '373_CR18', 'doi-asserted-by': 'publisher', 'author': 'P Sivapalan', 'year': '2021', 'unstructured': 'Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, Dahlin Bojesen R, Eklöf ' 'J, Browatzki A, et al. Azithromycin and hydroxychloroquine in ' 'hospitalised patients with confirmed COVID-19-a randomised ' 'double-blinded placebo-controlled trial. Eur Respir J. 2021. ' 'https://doi.org/10.1183/13993003.00752-2021.', 'journal-title': 'Eur Respir J', 'DOI': '10.1183/13993003.00752-2021'}, { 'key': '373_CR19', 'doi-asserted-by': 'publisher', 'author': 'F Ader', 'year': '2021', 'unstructured': 'Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, ' 'Diallo A, et al. An open-label randomized controlled trial of the effect ' 'of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and ' 'hydroxychloroquine in hospitalized patients with COVID-19. Clin ' 'Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.05.020.', 'journal-title': 'Clin Microbiol Infect', 'DOI': '10.1016/j.cmi.2021.05.020'}, { 'issue': '1', 'key': '373_CR20', 'doi-asserted-by': 'publisher', 'first-page': '9023', 'DOI': '10.1038/s41598-021-88509-9', 'volume': '11', 'author': 'Á Réa-Neto', 'year': '2021', 'unstructured': 'Réa-Neto Á, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO, Oliveira ' 'MC. An open-label randomized controlled trial evaluating the efficacy of ' 'chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. ' '2021;11(1):9023.', 'journal-title': 'Sci Rep'}, { 'issue': '4', 'key': '373_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'e216468', 'DOI': '10.1001/jamanetworkopen.2021.6468', 'volume': '4', 'author': 'G Reis', 'year': '2021', 'unstructured': 'Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park ' 'JJH, et al. Effect of early treatment with hydroxychloroquine or ' 'lopinavir and ritonavir on risk of hospitalization among patients with ' 'COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. ' '2021;4(4):e216468.', 'journal-title': 'JAMA Netw Open'}, { 'key': '373_CR22', 'doi-asserted-by': 'publisher', 'author': 'V Dubée', 'year': '2019', 'unstructured': 'Dubée V, Roy P-M, Vielle B, Parot-Schinkel E, Blanchet O, Darsonval A, ' 'et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: ' 'a placebo-controlled double blind trial. Clin Microbiol Infect. 2019. ' 'https://doi.org/10.1016/j.cmi.2021.03.005.', 'journal-title': 'Clin Microbiol Infect', 'DOI': '10.1016/j.cmi.2021.03.005'}, { 'issue': '4', 'key': '373_CR23', 'doi-asserted-by': 'publisher', 'first-page': '235', 'DOI': '10.1080/20477724.2021.1890887', 'volume': '115', 'author': 'LEB Galan', 'year': '2021', 'unstructured': 'Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima MA, Araújo AMM, et ' 'al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ' 'ivermectin in hospitalized patients with severe manifestations of ' 'SARS-CoV-2 infection. Pathog Glob Health. 2021;115(4):235–42.', 'journal-title': 'Pathog Glob Health'}, { 'key': '373_CR24', 'doi-asserted-by': 'publisher', 'first-page': '100773', 'DOI': '10.1016/j.eclinm.2021.100773', 'volume': '33', 'author': 'C Johnston', 'year': '2021', 'unstructured': 'Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, et ' 'al. Hydroxychloroquine with or without azithromycin for treatment of ' 'early SARS-CoV-2 infection among high-risk outpatient adults: a ' 'randomized clinical trial. EClinicalMedicine. 2021;33:100773.', 'journal-title': 'EClinicalMedicine'}, { 'key': '373_CR25', 'doi-asserted-by': 'publisher', 'author': 'AV Hernandez', 'year': '2021', 'unstructured': 'Hernandez AV, Ingemi J 3rd, Sherman M, Pasupuleti V, Barboza JJ, Piscoya ' 'A, et al. Impact of prophylactic hydroxychloroquine on people at high ' 'risk of COVID-19: a systematic review and meta-analysis. J Clin Med Res. ' '2021. https://doi.org/10.3390/jcm10122609.', 'journal-title': 'J Clin Med Res', 'DOI': '10.3390/jcm10122609'}, { 'key': '373_CR26', 'doi-asserted-by': 'publisher', 'author': 'AV Hernandez', 'year': '2021', 'unstructured': 'Hernandez AV, Phan MT, Rocco J, Pasupuleti V, Barboza JJ, Piscoya A, et ' 'al. Efficacy and safety of hydroxychloroquine for hospitalized COVID-19 ' 'patients: a systematic review and meta-analysis. J Clin Med Res. 2021. ' 'https://doi.org/10.3390/jcm10112503.', 'journal-title': 'J Clin Med Res', 'DOI': '10.3390/jcm10112503'}, { 'key': '373_CR27', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1080/20477724.2021.1936818', 'volume': '15', 'author': 'A Di Castelnuovo', 'year': '2021', 'unstructured': 'Di Castelnuovo A, Costanzo S, Cassone A, Cauda R, De Gaetano G, ' 'Iacoviello L. Hydroxychloroquine and mortality in COVID-19 patients: a ' 'systematic review and a meta-analysis of observational studies and ' 'randomized controlled trials. Pathog Glob Health. 2021;15:1–11.', 'journal-title': 'Pathog Glob Health'}, { 'issue': '1', 'key': '373_CR28', 'doi-asserted-by': 'publisher', 'first-page': '11974', 'DOI': '10.1038/s41598-021-91089-3', 'volume': '11', 'author': 'B Amani', 'year': '2021', 'unstructured': 'Amani B, Khanijahani A, Amani B. Hydroxychloroquine plus standard of ' 'care compared with standard of care alone in COVID-19: a meta-analysis ' 'of randomized controlled trials. Sci Rep. 2021;11(1):11974.', 'journal-title': 'Sci Rep'}, { 'issue': '1', 'key': '373_CR29', 'doi-asserted-by': 'publisher', 'first-page': '2349', 'DOI': '10.1038/s41467-021-22446-z', 'volume': '12', 'author': 'C Axfors', 'year': '2021', 'unstructured': 'Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, ' 'et al. Mortality outcomes with hydroxychloroquine and chloroquine in ' 'COVID-19 from an international collaborative meta-analysis of randomized ' 'trials. Nat Commun. 2021;12(1):2349.', 'journal-title': 'Nat Commun'}, { 'issue': '1', 'key': '373_CR30', 'first-page': '93', 'volume': '11', 'author': 'P Eze', 'year': '2021', 'unstructured': 'Eze P, Mezue KN, Nduka CU, Obianyo I, Egbuche O. Efficacy and safety of ' 'chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a ' 'systematic review and meta-analysis of randomized controlled trials. Am ' 'J Cardiovasc Dis. 2021;11(1):93–107.', 'journal-title': 'Am J Cardiovasc Dis'}, { 'key': '373_CR31', 'doi-asserted-by': 'publisher', 'author': 'B Yousefghahari', 'year': '2021', 'unstructured': 'Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri ' 'M, Heidari B, et al. Risk of COVID-19 infection in patients with ' 'rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin ' 'Rheumatol. 2021. https://doi.org/10.1007/s10067-021-05779-4.', 'journal-title': 'Clin Rheumatol', 'DOI': '10.1007/s10067-021-05779-4'}, { 'issue': '1', 'key': '373_CR32', 'doi-asserted-by': 'publisher', 'first-page': 'rkab014', 'DOI': '10.1093/rap/rkab014', 'volume': '5', 'author': 'K Pham', 'year': '2021', 'unstructured': 'Pham K, Torres H, Satlin MJ, Goyal P, Gulick RM. Failure of chronic ' 'hydroxychloroquine in preventing severe complications of COVID-19 in ' 'patients with rheumatic diseases. Rheumatol Adv Pract. ' '2021;5(1):rkab014.', 'journal-title': 'Rheumatol Adv Pract.'}, { 'key': '373_CR33', 'doi-asserted-by': 'publisher', 'author': 'R Cordtz', 'year': '2020', 'unstructured': 'Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, ' 'et al. Incidence and severeness of COVID-19 hospitalisation in patients ' 'with inflammatory rheumatic disease: a nationwide cohort study from ' 'Denmark. Rheumatology. 2020. ' 'https://doi.org/10.1093/rheumatology/keaa897.', 'journal-title': 'Rheumatology', 'DOI': '10.1093/rheumatology/keaa897'}, { 'issue': '8', 'key': '373_CR34', 'doi-asserted-by': 'publisher', 'first-page': 'e0255343', 'DOI': '10.1371/journal.pone.0255343', 'volume': '16', 'author': 'JE Dalton', 'year': '2021', 'unstructured': 'Dalton JE, Gunzler DD, Jain V, Perzynski AT, Dawson NV, Einstadter D, ' 'Tarabichi Y, Imrey PB, Lewis M, Kattan MW, Yao J, Taksler G, Berg KA, ' 'Krieger NI, Kaelber D, Jehi L, Kalra A. Mechanisms of socioeconomic ' 'differences in COVID-19 screening and hospitalizations. PLoS ONE. ' '2021;16(8):e0255343.', 'journal-title': 'PLoS ONE'}, { 'key': '373_CR35', 'doi-asserted-by': 'crossref', 'unstructured': 'Zerbo O, Lewis N, Fireman B, Goddard K, Skarbinski J, Sejvar JJ, ' 'Azziz-Baumgartner E, Klein NP. Population-based assessment of risks for ' 'severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021.', 'DOI': '10.1111/irv.12901'}, { 'issue': '7', 'key': '373_CR36', 'doi-asserted-by': 'publisher', 'first-page': 'e0255544', 'DOI': '10.1371/journal.pone.0255544', 'volume': '16', 'author': 'M Sandoval', 'year': '2021', 'unstructured': 'Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity ' 'of COVID-19 in hospital patients aged 18–29 years. PLoS ONE. ' '2021;16(7):e0255544.', 'journal-title': 'PLoS ONE'}, { 'issue': '7', 'key': '373_CR37', 'doi-asserted-by': 'publisher', 'first-page': 'e0255171', 'DOI': '10.1371/journal.pone.0255171', 'volume': '16', 'author': 'Y Zhang', 'year': '2021', 'unstructured': 'Zhang Y, Khullar D, Wang F, Steel P, Wu Y, Orlander D, Weiner M, Kaushal ' 'R. Socioeconomic variation in characteristics, outcomes, and healthcare ' 'utilization of COVID-19 patients in New York City. PLoS ONE. ' '2021;16(7):e0255171.', 'journal-title': 'PLoS ONE'}, { 'key': '373_CR38', 'doi-asserted-by': 'publisher', 'first-page': '101029', 'DOI': '10.1016/j.eclinm.2021.101029', 'volume': '38', 'author': 'CH Lo', 'year': '2021', 'unstructured': 'Lo CH, Nguyen LH, Drew DA, Warner ET, Joshi AD, Graham MS, Anyane-Yeboa ' 'A, Shebl FM, Astley CM, Figueiredo JC, Guo CG, Ma W, Mehta RS, Kwon S, ' 'Song M, Davies R, Capdevila J, Sudre CH, Wolf J, Cozier YC, Rosenberg L, ' 'Wilkens LR, Haiman CA, Marchand LL, Palmer JR, Spector TD, Ourselin S, ' 'Steves CJ, Chan AT, COPE Consortium. Race, ethnicity, community-level ' 'socioeconomic factors, and risk of COVID-19 in the United States and the ' 'United Kingdom. EClinical Medicine. 2021;38:101029.', 'journal-title': 'EClinical Medicine.'}], 'container-title': 'Rheumatology and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40744-021-00373-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40744-021-00373-1/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40744-021-00373-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 11, 6]], 'date-time': '2021-11-06T22:11:29Z', 'timestamp': 1636236689000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40744-021-00373-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 9, 16]]}, 'references-count': 38, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['373'], 'URL': 'http://dx.doi.org/10.1007/s40744-021-00373-1', 'relation': {}, 'ISSN': ['2198-6576', '2198-6584'], 'subject': ['Immunology and Allergy', 'Rheumatology'], 'container-title-short': 'Rheumatol Ther', 'published': {'date-parts': [[2021, 9, 16]]}, 'assertion': [ { 'value': '14 July 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '6 September 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '16 September 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}